-
1.
Cole E, Landsberg D, Russell D, et al..: A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transpl 2001; 72:845–850.
-
2.
Birkeland SA: Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate maintenance therapy. Transpl 1998; 66:1207–1210.
-
3.
Matas AJ, Kandaswamy R, Gillingham KJ, et al..: Prednisone-free maintenance immunosuppression: A 5-year experience. Am J Transpl 2005; 5:2473–2478.
-
4.
Kaufman DB, Leventhal JR, Axelrod D, et al..: Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction—long-term results, Am J Transpl 2005; 5:2539–2548.
-
5.
Opelz G, Dohler B, Laux G: Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transpl 2005; 5:720–728.
-
6.
Luan FL, Steffick DE, Gadegbeku C, Norman SP, Wolfe R, Ojo AO: Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transpl, 2009; 9:160–168.
-
7.
Woodle ES, First MR, Pirsch J, et al..: A prospective, randomized, double-blind, placebo controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term low-dose corticosteroid therapy. Ann Surg 2008; 248: 564–577.
-
8.
Hricik DE, O’Toole MA, Schulak JA, Herson J: Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993; 4:1300–1305.
-
9.
Sinclair NR: Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992; 147:645–657.
-
10.
Adams PL: Long-term patient survival: strategies to improve overall health. Am J Kidney Dis 2006; 47 (4 Suppl 2): S65–S85.
-
11.
Pascual J, Zamora J, Galeano C, et al..: Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2009; 1: CD005632.
-
12.
Rostaing L, Cantarovich D, Mourad G, et al..: Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transpl 2005; 79:807–814.
-
13.
Shibatani M, Fujioka M, Arai Y, et al..: Degree of corticosteroid treatment within the first 2 months of renal transplantation has a strong influence on the incidence of osteonecrosis of the femoral head. Acta Orthop 2008; 79:631–636.
-
14.
O’Shaughnessy EA, Dahl DC, Smith CL, Kasiske BL: Risk factors for fractures in kidney transplantation. Transpl 2002; 74:362–366.
-
15.
Gaber LW, Gaber AO, Hathaway DK, Vera SR, Shokouh-Amiri MH: Routine early biopsy of allografts with delayed function: correlation of histopathology and transplant outcome. Clin Transpl 1996; 10:629–634.
-
16.
Augustine JJ, Siu DS, Clemente MJ, et al..: Pre-transplant IFN-gamma ELISPOTs are associated with posttransplant renal function in African American renal transplant recipients. Am J Transplant 2005; 5:1971–1975.
-
17.
Basadonna GP, Matas AJ, Gillingham KJ, et al..: Early versus late acute renal allograft rejection: impact on chronic rejection. Transpl 1993; 55:993–995.
-
18.
Humar A, Gillingham K, Kandaswamy R, Payne W, Matas A: Steroid avoidance regimens: a comparison of outcomes with maintenance steroids versus continued steroid avoidance in recipients having an acute rejection episode. Am J Transpl 2007; 7:1948–1953.
-
19.
Vítko S, Klinger M, Salmela K, et al..: Two corticosteroid-free regimens—tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil—in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Transpl 2005; 80:1734–1741.
Avoiding Steroids can be Successful Strategy After Kidney Transplantation…
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory